A Phase 1 Study of ABBV|011 as a Single ...

A Phase I First-in-Human Study of ABBV-011, a Seizure-Related ...

AbstractPurpose:. Seizure-related homolog protein 6 (SEZ6) is a novel target expressed in small cell lung cancer (SCLC). ABBV-011, a SEZ6-targeted.

A Phase I First-in-Human Study of ABBV-011, a Seizure-Related ...

A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer.

A Phase 1 Study of ABBV-011 as a Single-Agent and in ...

This is a multicenter, open-label, Phase 1 study of ABBV-011 given as a single agent and in combination with budigalimab (ABBV-181) in participants with ...

First-in-human study of ABBV-011, a seizure-related homolog ...

3002Background: Small cell lung cancer (SCLC) has a dismal prognosis and new therapies are urgently needed. SEZ6 is a transmembrane protein ...

NCT03639194 - ClinicalTrials.gov

A Study of ABBV-011 Alone and in Combination With Budigalimab ...

This is a multicenter, open-label, Phase 1 study of ABBV-011 given as a ... The study consists of 4 parts: Part A is a single-agent ABBV-011 dose ...

A Phase 1 Study of ABBV-011 as a Single ... - Scholars@Duke grant

A Phase 1 Study of ABBV-011 as a Single-Agent and in Combination with Budigalimab (ABBV-181) in Subjects with Relapsed or Refractory Small Cell Lung Cancer.

ABBV-011 Achieves Antitumor Activity and Tolerable Safety in Small ...

The investigational agent, ABBV-011, is showing promise, according to results from a phase 1 clinical trial.

Research and trials - Orphanet

Knowledge on rare diseases and orphan drugs · Search for a clinical trial · [M17-327] A Phase I Study of ABBV-011 as a Single-Agent and in Combination With ...

ABBV-011 Demonstrates Preliminary Efficacy, Safety in R/R SCLC

... phase 1 trial ... The study is comprised of 4 parts: part A is a single-agent ...

ADC With Novel SEZ6 Target Well-Tolerated With Preliminary ...

ABBV-011 was well-tolerated and demonstrated antitumor activity in a first-in-human, phase 1 trial of patients with relapsed/refractory SCLC ...

SC-011 - Drug Targets, Indications, Patents - Patsnap Synapse

A Phase I Study of ABBV-011 as a Single-Agent and in Combination With Budigalimab (ABBV-181) in Subjects With Relapsed or Refractory Small Cell Lung Cancer.

CLINICAL TRIALS - AbbVie Science

... Single Agent and in Combination With ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors · M17-327: A Phase I Study of ABBV-011 as a Single ...

Phase I safety and pharmacokinetic study of CT-011, a ... - PubMed

A single administration of 0.2 to 6.0 mg/kg of CT-011 is safe and well tolerated in patients with advanced hematologic malignancies.

A Phase 1 First-in Human Multi-Center Open Label Dose-Escalation ...

... Study to Determine the Safety Tolerability Pharmacokinetics and RP2D of livmoniplimab (ABBV-151) as a Single Agent and in Combination with budigalimab (ABBV ...

770 Safety, efficacy, and pharmacokinetic results from a phase I first ...

Acknowledgements AbbVie and the authors thank all the trial investigators and the patients who participated in this clinical trial. Medical writing support was ...

AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO ...

New safety and efficacy data from a Phase 1 study (NCT05029882) of ABBV ... PICCOLO is a single-arm Phase 2 trial evaluating the efficacy ...

A Phase 1 First-in-Human Study Evaluating Safety ...

ABBV-969 is an investigational drug being developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). There are ...

A First-in-Human Phase 1 Study of ABBV-525, a Small-Molecule ...

This phase 1 study evaluates the clinical candidate MALT1 inhibitor ABBV-525 as monotherapy in pts with relapsed or refractory (R/R) B-cell NHL.

A Phase I Study of ABBV-011 as a Single-Agent and in Combination ...

A Phase I Study of ABBV-011 as a Single-Agent and in Combination With Budigalimab (ABBV-181) in Subjects With Relapsed or Refractory Small Cell ...